You just read:

Exploratory Analysis of the Phase I/II CHRYSALIS Study of gilteritinib Demonstrates First Molecular Response to FLT3 Inhibitor in Acute Myeloid Leukemia

News provided by

Astellas

Jun 06, 2017, 10:45 ET